Lifeboat Foundation

In this review, we undertake a critical appraisal of eight published studies providing first evidence that a history of attention-deficit/hyperactivity disorder (ADHD) may increase risk for the later-life development of a neurodegenerative disease, in particular Lewy body diseases (LBD), by up to five-fold. Most of these studies have used data linked to health records in large population registers and include impressive sample sizes and adequate follow-up periods. We identify a number of methodological limitations as well, including potential diagnostic inaccuracies arising from the use of electronic health records, biases in the measurement of ADHD status and symptoms, and concerns surrounding the representativeness of ADHD and LBD cohorts. Consequently, previously reported risk associations may have been underestimated due to the high likelihood of potentially missed ADHD cases in groups used as “controls”, or alternatively previous estimates may be inflated due to the inclusion of confounding comorbidities or non-ADHD cases within “exposed” groups that may have better accounted for dementia risk. Prospective longitudinal studies involving well-characterized cases and controls are recommended to provide some reassurance about the validity of neurodegenerative risk estimates in ADHD.

Attention-deficit hyperactivity disorder (ADHD) is a psychiatric disorder beginning in childhood that is characterized by core symptoms of inattention, impulsivity, and hyperactivity (Biederman and Faraone, 2005; American Psychiatric Association, 2013; Faraone et al., 2015). Diagnostic criteria require symptoms to present in early childhood, before age 12, and cause impairment in daily activities in more than one setting (e.g., home, school, social environment, and/or interpersonal relationships; American Psychiatric Association, 2013). Although it is largely considered a childhood disorder, 40–60% of cases of ADHD persist into adulthood (Culpepper and Mattingly, 2010; Michielsen et al., 2012; Volkow and Swanson, 2013; Asherson et al., 2016), and the overall prevalence of adult ADHD ranges from 2 to 4% (Kieling and Rohde, 2012; Fayyad et al., 2017).

ADHD may persist into later life as well. Roughly 3% of adults over age 50 suffer from significant symptoms of attention-deficit/hyperactivity disorder (ADHD; Michielsen et al., 2012; Kooij et al., 2016), often presenting as executive dysfunction (e.g., absent-mindedness) and memory impairments (e.g., forgetfulness or difficulty learning new things; Rosler et al., 2010; Thorell et al., 2017; Callahan et al., 2021). These symptoms overlap with those of early neurodegenerative disease (Ivanchak et al., 2012; Pollack, 2012; Goodman et al., 2016; Callahan et al., 2017), and it is currently unclear whether ADHD is associated with an increased neurodegenerative risk, or if it is being misdiagnosed due to symptom overlap (Callahan et al., 2017). Clarifying this issue is crucial to reduce dementia misdiagnoses, and to guide treatment, which will differ depending on whether the disease course is assumed to be neurodegenerative or not.

A team of researchers in the Faculty of Engineering of The University of Hong Kong (HKU) has developed a coin-sized system that can read weak electrochemical signals and can be used for personalized health monitoring and the measurement of such conditions as diabetes, cardiovascular diseases and mental health. The discovery was featured on the cover of Analytical Chemistry.

The PERfECT System—an acronym for Personalized Electronic Reader for Electrochemical Transistors—is the world’s smallest system of its kind, measuring 1.5 cm x 1.5 cm x 0.2 cm and weighing only 0.4 gram. It is easily wearable, for instance integrated with a smartwatch or as a patch, to allow for continuous monitoring of biosignals such as glucose levels and antibody concentrations in blood and even sweat.

Continue reading “Coin-sized wearable biosensing platform for digital health” »

Researchers at Aalto University have developed a bio-based adhesive that can replace formaldehyde-containing adhesives in wood construction. The main raw material in the new adhesive is lignin, a structural component of wood and a by-product of the pulp industry that is usually burned after wood is processed. As an alternative to formaldehyde, lignin offers a healthier and more carbon-friendly way to use wood in construction.

The carbon footprint of timber construction is significantly lower than concrete construction, and timber construction has often been viewed as better for the health of human occupants as well. However, wood panels still use adhesives made from fossil raw materials. They contain formaldehyde, which can be harmful to health, especially for those working in the adhesive manufacturing process. People living in or visiting buildings can also be exposed to toxic formaldehyde from wood panels.

Lignin, on the other hand, comes from wood itself. It binds cellulose and hemicellulose together and gives wood its tough, strong structure. Lignin accounts for about a quarter of the weight of wood and is produced in huge quantities in the pulp and bioprocessing industry. Only two to five percent of the lignin produced is used, and the rest is burned in factories for energy.

Agility Robotics recently raised $150 million USD in part from Amazon to further develop its humanoid robot called “Digit” for logistics automation. New wearable, bendable, stretchable neuromorphic AI chip monitors health in real time. New machine learning model from MIT does college level math at a human level.

AI News Timestamps:
0:00 Humanoid Robot Worker For Amazon Automation.
3:00 New Wearable AI Chip.
5:08 New Machine Learning Math Model.

Continue reading “Humanoid Robotics For Amazon Automation | New Wearable AI Chip | New Machine Learning Math Model” »

An Israeli company has launched a clinical trial to determine if its innovative microbiome-based therapeutic could increase the responsiveness of some cancer patients to immunotherapy.

The microbiome is gut bacteria – trillions of microorganisms that live in the intestinal tract and play a role in digestion, immunity and many other aspects of health.

Rehovot-based Biomica, a subsidiary of Evogene, dosed its first patients in a Phase I clinical trial at Rambam Health Care Campus last month with a new drug – BMC128 – that is expected to help patients who do not respond to immunotherapy. Specifically, the company hopes the trial will demonstrate the safety, tolerability and preliminary clinical effectiveness of its BMC128 microbiome-based immuno-oncology drug candidate in combination with immune checkpoint inhibitor (ICI) immunotherapy.

Comotion_design/iStock.

The U.S. Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative is a collaboration among the National Institutes of Health, Defense Advanced Research Projects Agency, National Science Foundation, Food and Drug Administration, Intelligence Advanced Research Projects Activity, and others. Since its inception in 2013, its goal has been to develop and use new technologies to examine how each neuron and neural circuit come together to “record, process, utilize, store, and retrieve vast quantities of information, all at the speed of thought.”

The FDA will allow health-care providers to administer the shots through intradermal injection, or between the layers of the skin, for adults.

The space between the planets in our solar system is filled with a wispy sea of charged particles that flow out from the Sun’s atmosphere. This particle population is augmented by cosmic rays — speedy protons and atomic nuclei accelerated in extreme environments across the universe — which ebb and flow against the 11-year solar activity cycle. This undulating particle background is punctuated by bursts of high-energy particles from the Sun, which can be unleashed suddenly in violent solar storms.

Spacecraft that venture out from the protection of Earth’s magnetic field must navigate this ocean of particles and weather solar storms. And if we someday wish to send astronauts to other planets, we’ll need to know how high-energy solar particles, which pose a risk to the health of astronauts and electronic systems alike, travel through the solar system.

In a new publication, a team led by Shuai Fu (Macau University of Science and Technology), Zheyi Ding (China University of Geosciences), and Yongjie Zhang (Chinese Academy of Sciences) studied the high-energy solar particles produced in an event in November 2020, when the Sun emitted a solar flare and a massive explosion of solar plasma called a coronal mass ejection.

Science, Technology, Health, Physics, Chemistry stay Updated.

Scientists from The Australian National University (ANU) and James Cook University (JCU) have identified an “exquisite” natural mechanism that helps plants limit their water loss with little effect on carbon dioxide (CO₂) intake—an essential process for photosynthesis, plant growth and crop yield.